Skip to main content

Table 1 The baseline characteristics of enrolled women

From: A randomized controlled trial of dihydroartemisinin-piperaquine, artesunate-mefloquine and extended artemether-lumefantrine treatments for malaria in pregnancy on the Thailand-Myanmar border

Baseline characteristic

All (n = 511)

DP (n = 172)

ASMQ (n = 169)

AL+ (n = 170)

EGA at first ANC (week)^

15 [10–22]

15 [10–20]

15 [9–23.5]

15 [10–22.5]

EGA malaria (week)^

26 [19–33]

25 [19–32]

27 [19–34]

26 [19–32]

Trimester

 1st

46 (9.0%)

13 (7.6%)

15 (8.9%)

18 (10.6%)

 2nd

236 (46.2%)

84 (48.8%)

74 (43.8%)

78 (45.9%)

 3rd

229 (44.8%)

75 (43.6%)

80 (47.3%)

74 (43.5%)

Age (years)

25.7 (6.8)

25.7 (6.8)

26.3 (6.7)

25.1 (7.0)

Gravidity

 1

171 (33.5%)

60 (34.9%)

46 (27.2%)

65 (38.2%)

 2

98 (19.2%)

30 (17.4%)

35 (20.7%)

33 (19.4%)

 ≥3

242 (47.4%)

82 (47.7%)

88 (52.1%)

72 (42.4%)

Parity

 0

204 (39.9%)

71 (41.3%)

57 (33.7%)

76 (44.7%)

 1

97 (19.0%)

36 (20.9%)

32 (18.9%)

29 (17.1%)

 ≥2

210 (41.1%)

65 (37.8%)

80 (47.3%)

65 (38.2%)

Smoking

101 (19.8%)

32 (18.6%)

34 (20.1%)

35 (20.6%)

Height (cm)

151.0 (5.4)

151.2 (5.3)

151.1 (5.5)

150.8 (5.5)

Weight (kg)

51.7 (7.6)

52.4 (8.3)

52.0 (7.4)

50.8 (7.0)

Fever (temperature ≥ 37.5)

146 (28.6%)

45 (26.2%)

48 (28.4%)

53 (31.2%)

Fever (including history of fever)

340 (66.5%)

115 (66.9%)

113 (66.9%)

112 (65.9%)

Haematocrit (%)

32.1 (4.0)

32.1 (4.1)

32.3 (4.1)

32.0 (3.9)

Anaemia

 No anaemia

406 (79.5%)

138 (80.2%)

135 (79.9%)

133 (78.2%)

 Moderate anaemia

105 (20.5%)

34 (19.8%)

34 (20.1%)

37 (21.8%)

 Severe anaemia

0 (0.0%)

0 (0.0%)

0 (0.0%)

0 (0.0%)

First recorded malaria in pregnancy

277 (78.5%)

89 (73.6%)

94 (83.9%)

94 (78.3%)

Species

 Pf mono-infection

142 (27.8%)

46 (26.7%)

52 (30.8%)

44 (25.9%)

 Pv mono-infection

353 (69.1%)

121 (70.3%)

112 (66.3%)

120 (70.6%)

 Pf and Pv coinfection

15 (2.9%)

4 (2.3%)

5 (3.0%)

6 (3.5%)

 Pm mono-infection

1 (0.2%)

1 (0.6%)

0 (0.0%)

0 (0.0%)

Pf parasitaemia (/uL)*

5689 (16–207994)

4561 (16–207994)

5805 (16–124595)

6936 (96–120199)

Pv parasitaemia (/uL)*

658 (16–83524)

674 (16–83524)

651 (16–29893)

648 (16–40694)

Presence of Pf gametocytes

24 (4.7%)

12 (7.0%)

6 (3.6%)

6 (3.5%)

Presence of Pv gametocytes

233 (45.6%)

81 (47.1%)

66 (39.1%)

86 (50.6%)

  1. AL+ artemether-lumefantrine extended regimen, ANC antenatal care, ASMQ artesunate-mefloquine, BMI body mass index, DP dihydroartemisinin-piperaquine, EGA estimated gestational age, Pf Plasmodium falciparum, Pm Plasmodium malariae, Pv Plasmodium vivax, SD standard deviation. Data are presented as mean (standard deviation), number (%), ^median [interquartile range] or *geometric mean (range)
  2. Anaemia was defined as a haematocrit of 20-29% (moderate) or less than 20% (severe)